Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12
Venture Financing 13
Aerie Pharma Raises Additional USD12 Million in Venture Financing 13
Aerie Pharma Raises US$3 Million In Venture Financing 14
Partnerships 15
ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
Licensing Agreements 17
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17
Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18
Aerie Pharma Enters into Licensing Agreement with GrayBug 19
Equity Offering 20
Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20
Aerie Pharma Raises USD75 Million in Public Offering of Shares 22
Aerie Pharma Raises USD75 Million in Public Offering of Shares 24
Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26
Aerie Pharma Completes IPO For US$77.3 Million 27
Debt Offering 29
Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29
Aerie Pharmaceuticals Inc – Key Competitors 31
Aerie Pharmaceuticals Inc – Key Employees 32
Aerie Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Strategy And Business Planning 35
Oct 23, 2018: Aerie Pharmaceuticals establishes GMP PRINT production facility in an expanded global headquarters 35
Financial Announcements 36
Nov 06, 2018: Aerie Pharmaceuticals reports third quarter 2018 financial results and provides business update 36
Aug 08, 2018: Aerie Pharmaceuticals reports second quarter 2018 financial results and provides business update 38
May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update 39
Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance 40
Nov 08, 2017: Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 42
Aug 01, 2017: Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43
May 02, 2017: Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 44
Mar 07, 2017: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 45
Corporate Communications 46
Sep 12, 2018: Aerie Pharmaceuticals names David W. Gryska as Board Director 46
Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region 47
Aug 28, 2017: Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director 48
Apr 24, 2017: Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance 49
Apr 10, 2017: Aerie Pharmaceuticals Announces Expansion of Commercialization Team 50
Product News 51
12/18/2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension 51
08/15/2018: Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study 52
05/03/2017: Envisia Therapeutics Announces New Data On ENV1105 At ASCRS 2017 Annual Meeting 53
04/30/2018: Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa (netarsudil ophthalmic solution) 0.02% 54
Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure 55
Product Approvals 56
Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02% 56
Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02% 57
Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer 58
May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02% 59
Mar 01, 2017: Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% 60
Clinical Trials 61
Oct 09, 2018: Aerie Pharmaceuticals Announces Drug Application for Regulatory Approval Accepted for Review in Europe 61
Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan 62
Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02% 63
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12
Aerie Pharma Raises Additional USD12 Million in Venture Financing 13
Aerie Pharma Raises US$3 Million In Venture Financing 14
ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17
Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18
Aerie Pharma Enters into Licensing Agreement with GrayBug 19
Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20
Aerie Pharma Raises USD75 Million in Public Offering of Shares 22
Aerie Pharma Raises USD75 Million in Public Offering of Shares 24
Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26
Aerie Pharma Completes IPO For US$77.3 Million 27
Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29
Aerie Pharmaceuticals Inc, Key Competitors 31
Aerie Pharmaceuticals Inc, Key Employees 32
Aerie Pharmaceuticals Inc, Other Locations 34
Aerie Pharmaceuticals Inc, Subsidiaries 34
List of Figures
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10